Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Deep learning for cardiovascular medicine: a practical primer
Krittanawong, Chayakrit , Johnson, Kipp W. , Wang, Zhen , Aydar, Mehmet , Baber, Usman, Min, James K. , Tang, W.H. Wilson , Halperin, Jonathan L. , Narayan, Sanjiv M. , Tang, W H Wilson , Rosenson, Robert S. , Baber, Usman , Narayan, Sanjiv M

Mayo Clinic

European Heart Journal | January 22, 2019 | Volume: 40 | Issue: 25 | Pages: 2058-2073

10.1093/eurheartj/ehz056 | PMID 30815669 Get It

Abstract Deep learning (DL) is a branch of machine learning (ML) showing increasing promise in medicine, to assist in data classification, novel disease phenotyping and complex decision making. Deep learning is a form of ML typically implemented via multi-layered neural networks. Deep learning has accelerated by recent advances in computer hardware and algorithms and is increasingly applied in e-commerce, finance, and voice and image recognition to learn and classify complex datasets. The current medical literature shows both strengths and limitations of DL. Strengths of DL include its ability to automate medical image interpretation, enhance clinical decision-making, identify novel phenotypes, and select better treatment pathways in complex diseases. Deep learning may be well-suited to cardiovascular medicine in which haemodynamic and electrophysiological indices are increasingly captured on a continuous basis by wearable devices as well as image segmentation in cardiac imaging. However, DL also has significant weaknesses including difficulties in interpreting its models (the ‘black-box’ criticism), its need for extensive adjudicated (‘labelled’) data in training, lack of standardization in design, lack of data-efficiency in training, limited applicability to clinical trials, and other factors. Thus, the optimal clinical application of DL requires careful formulation of solvable problems, selection of most appropriate DL algorithms and data, and balanced interpretation of results. This review synthesizes the current state of DL for cardiovascular clinicians and investigators, and provides technical context to appreciate the promise, pitfalls, near-term challenges, and opportunities for this exciting new area.
Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study
Cho, Yeoungjee , Sautenet, Bénédicte , Gutman, Talia , Rangan, Gopala K. , Craig, Jonathan C. , Ong, Albert , Chapman, Arlene B., Coolican, Helen, Kao, Juliana T‐W, Gansevoort, Ron T. , Harris, Tess , Torres, Vicente E. , Pei, York , Ryan, Jessica , Johnson, David W. , Viecelli, Andrea K. , Geneste, Claire, Oh, Yun Kyu , Teixeira‐Pinto, Armando , Logeman, Charlotte , Howell, Martin , Ju, Angela, Manera, Karine , Tong, Allison , Torres, Vicente E , Johnson, David W , Howell, Martin , Ong, Albert C M , Ahn, Curie , Kao, Juliana Tze‐Wah , Perrone, Ronald D. , Kerr, Peter G. , Kim, Hyunsuk , Kim, Yaerim , Cho, Yeoungjee

Mayo Clinic

Nephrology | January 21, 2019 | Volume: 24 | Issue: 12 | Pages: 1214-1224

10.1111/nep.13566 | PMID 30663163 Get It

ABSTRACTAimPatients with autosomal dominant polycystic kidney disease (ADPKD) are at increased risk of premature mortality, morbidities and complications, which severely impair quality of life. However, patient‐centered outcomes are not consistently reported in trials in ADPKD, which can limit shared decision‐making. We aimed to identify outcomes important to patients and caregivers and the reasons for their priorities.MethodsNominal group technique was adopted involving patients with ADPKD and caregivers who were purposively selected from eight centres across Australia, France and the Republic of Korea. Participants identified, ranked and discussed outcomes for trials in ADPKD. We calculated an importance score (0–1) for each outcome and conducted thematic analyses.ResultsAcross 17 groups, 154 participants (121 patients, 33 caregivers) aged 19 to 78 (mean 54.5 years) identified 55 outcomes. The 10 highest ranked outcomes were: kidney function (importance score 0.36), end‐stage kidney disease (0.32), survival (0.21), cyst size/growth (0.20), cyst pain/bleeding (0.18), blood pressure (0.17), ability to work (0.16), cerebral aneurysm/stroke (0.14), mobility/physical function (0.12), and fatigue (0.12). Three themes were identified: threatening semblance of normality, inability to control and making sense of diverse risks.ConclusionFor patients with ADPKD and their caregivers, kidney function, delayed progression to end‐stage kidney disease and survival were the highest priorities, and were focused on achieving normality, and maintaining control over health and lifestyle. Implementing these patient‐important outcomes may improve the meaning and relevance of trials to inform clinical care in ADPKD.
Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease
Wang, Ming‐Hsi , Friton, Jessica, Raffals, Laura E. , Leighton, Jonathan A. , Pasha, Shabana F., Picco, Michael F., Monroe, Kelly, Nix, Billy D., Newberry, Rodney D. , Faubion, William A. , Friton, Jessica J, Cushing, Kelly C. , Newberry, Rodney D

Mayo Clinic

Journal of Crohn's and Colitis | January 21, 2019 | Volume: 13 | Issue: 8 | Pages: 1036-1043

10.1093/ecco-jcc/jjz017 | PMID 30689765 Get It

AbstractBackgroundIt is important to identify patients with inflammatory bowel disease [IBD] refractory to anti-tumour necrosis factor [TNF] therapy, to avoid potential adverse effects and to adopt different treatment strategies. We aimed to identify and validate clinical and genetic factors to predict anti-TNF response in patients with IBD.Materials and MethodsMayo Clinic and Washington University IBD genetic association study cohorts were used as discovery and replicate datasets, respectively. Clinical factors included sex, age at diagnosis, disease duration and phenotype, disease location, bowel resection, tobacco use, family history of IBD, extraintestinal manifestations, and response to anti-TNF therapy.ResultsOf 474 patients with IBD treated with anti-TNF therapy, 41 [8.7%] were refractory to therapy and 433 [91.3%] had response. Multivariate analysis showed history of immunomodulator use (odds ratio 10.2, p = 8.73E-4) and bowel resection (odds ratio 3.24, p = 4.38E-4) were associated with refractory response to anti-TNF agents. Among genetic loci, two [rs116724455 in TNFSF4/18, rs2228416 in PLIN2] were successfully replicated and another four [rs762787, rs9572250, rs144256942, rs523781] with suggestive evidence were found. An exploratory risk model predictability [area under the curve] increased from 0.72 [clinical predictors] to 0.89 after adding genetic predictors. Through identified clinical and genetic predictors, we constructed a preliminary anti-TNF refractory score to differentiate anti-TNF non-responders (mean [standard deviation] score, 5.49 [0.99]) from responders (2.65 [0.39]; p = 4.33E-23).ConclusionsNovel and validated genetic loci, including variants in TNFSF, were found associated with anti-TNF response in patients with IBD. Future validation of the exploratory risk model in a large prospective cohort is warranted.
Comparison of Donor Cornea Endothelial Cell Density Determined by Eye Banks and by a Central Reading Center in the Cornea Preservation Time Study
Benetz, Beth Ann , Stoeger, Christopher G. , O’Brien, Robert , Szczotka‐Flynn, Loretta , Ayala, Allison R. , Menegay, Harry, Bedard, Peter, Clover, Jameson , McCoy, Kristen, Song, Jonathan, Lass, Jonathan H. , Group, on behalf of the Cornea Preservation Time Study, Patel, Sanjay V. , Maguire, Maureen G. , Gupta, Pankaj C., Group, on behalf of the Cornea Preservation Time Study

Mayo Clinic

Cornea | January 19, 2019 | Volume: 38 | Issue: 4 | Pages: 426-432

10.1097/ico.0000000000001846 | PMID 30664048 Get It

Purpose: To evaluate agreement between eye banks (EBs) and a reading center on endothelial cell density (ECD) determinations in the Cornea Preservation Time Study. Methods: The Cornea Image Analysis Reading Center (CIARC) performed variable frame image analysis on EB-obtained–preoperative central endothelial images (after lamellar dissection for Descemet stripping automated endothelial keratoplasty by the EBs or before shipping, if surgeon prepared) to determine ECD. The EBs performed their usual method of ECD determination. The CIARC and EBs also provided ECD determinations from screening central endothelial images taken by the EBs during donor evaluation. Two independent masked CIARC readers determined ECD with measurements averaged. Results: The mean preoperative ECD was 15 cells/mm2 greater by the EBs than by CIARC (N = 1286, P < 0.001) with 95% limits of agreement of (−644, 675 cells/mm2). The limits of agreement in preoperative ECD were wider in the After-Lamellar-Dissection Group (−687, 683 cells/mm2) than in the Before Shipping Group [(−505, 633 cells/mm2); P = 0.03]. The EBs-determined preoperative ECD was within 10% of the CIARC-determined ECD for 886 (69%) image sets, with 236 (18%) higher by >10% and 164 (13%) lower by >10%. Excellent agreement appeared between the EBs and CIARC when 100–300 cells could be analyzed in contrast to <100 cells (SD = 308 cells/mm2 vs. SD = 603 cells/mm2; P < 0.001). Conclusions: The mean ECD by the EBs and CIARC were similar, but there was considerable variability between determinations for individual corneas. Agreement improved between the 2 measurements when more than 100 cells were able to be analyzed.
The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations
Goodman, Brent P., Carter, Jonathan L, Wingerchuk, Dean M. , Valencia-Sánchez, Cristina

Mayo Clinic

Multiple Sclerosis Journal | January 18, 2019 | Volume: 25 | Issue: 6 | Pages: 758-765

10.1177/1352458518823482 | PMID 30657008 Get It

Diverse acute neurological injuries may cause acute cardiopulmonary events including neurogenic pulmonary edema (NPE) and neurogenic stunned myocardium (NSM). The mechanism is probably mediated by sympathetic nervous system activation. Focal central nervous system (CNS) lesions, such as demyelinating lesions in multiple sclerosis (MS), may also cause cardiopulmonary disturbances. We aim to review the acute cardiopulmonary events associated with MS relapses. We performed a literature search using PubMed, and selected case reports of acute cardiac and/or pulmonary events related to MS exacerbations. We grouped these events into three categories: 1) NPE with normal cardiac function; 2) NSM and Takotsubo cardiomyopathy (TTC); 3) coexisting myocardial dysfunction and pulmonary edema. In some cases, cardiac and pulmonary symptoms preceded the onset of neurological symptoms. The majority of cases were associated with acute demyelinating lesions located in the medulla. Acute brainstem MS relapses, with demyelinating lesions affecting the medulla, may cause acute cardiac and pulmonary events presumably secondary to sympathetic hyperstimulation. Specific regions in the medulla that regulate cardiac function, systemic blood pressure and pulmonary hydrostatic pressure seem to be responsible for these events.
Procedural predictors of epidural blood patch efficacy in spontaneous intracranial hypotension
Pagani-Estévez, Gabriel L., Cutsforth‐Gregory, Jeremy K. , Mokri, Bahram, Piepgras, David G., Mauck, William D. , Eldrige, Jason S. , Watson, James C. , Morris, Jonathan M.

Mayo Clinic

Regional Anesthesia & Pain Medicine | January 13, 2019 | Volume: 44 | Issue: 2 | Pages: 212-220

10.1136/rapm-2018-000021 | PMID 30636714 Get It

Background and objective Epidural blood patch (EBP) is a safe and effective treatment for spontaneous intracranial hypotension (SIH), but clinical and procedural variables that predict EBP efficacy remain nebulous. Methods This study is an institutional review board-approved retrospective case series with dichotomized EBP efficacy defined at 3 months. The study included 202 patients receiving 604 EBPs; iatrogenic cerebrospinal fluid leaks were excluded. Results Of the EBPs, 473 (78%) were single-level, 349 (58%) lumbar, 75 (12%) bilevel, and 56 (9%) multilevel (≥3 levels). Higher volume (OR 1.64; p<0.0001), bilevel (3.17, 1.91–5.27; p<0.0001), and multilevel (117.3, 28.04–490.67; p<0.0001) EBP strategies predicted greater efficacy. Only volume (1.64, 1.47–1.87; p<0.0001) remained significant in multivariate analysis. Site-directed patches were more effective than non-targeted patches (8.35, 0.97–72.1; p=0.033). Lower thoracic plus lumbar was the most successful bilevel strategy, lasting for a median of 74 (3–187) days. Conclusions In this large cohort of EBP in SIH, volume, number of spinal levels injected, and site-directed strategies significantly correlated with greater likelihood of first EBP efficacy. Volume and leak site coverage likely explain the increased efficacy with bilevel and multilevel patches. In patients with cryptogenic leak site, and either moderate disability, negative prognostic brain MRI findings for successful EBP, or failed previous lumbar EBP, a low thoracic plus lumbar bilevel EBP strategy is recommended. Multilevel EBP incorporating transforaminal administration and fibrin glue should be considered in patients refractory to bilevel EBP. An algorithmic approach to treating SIH is proposed.
Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis
Al‐Mansour, Zeina , Li, Hongli , Cook, James R. , Couban, Stephen, Stewart, Douglas A. , Shea, Thomas C., Smith, Sonali M. , Marcellus, Deborah, Barton, Kevin, Mills, Glenn, Forman, Stephen J. , Leonard, John P. , Fisher, Richard I., Friedberg, Jonathan W. , Stiff, Patrick J. , Constine, Louis S , Porcu, Pierluigi , Winter, Jane N. , Kahl, Brad S. , LeBlanc, Michael , Rimsza, Lisa M.

Mayo Clinic

Leukemia & Lymphoma | January 10, 2019 | Volume: 60 | Issue: 8 | Pages: 1934-1941

10.1080/10428194.2018.1563691 | PMID 30628511 Get It

Bilateral Vestibular Hypofunction in Neurosarcoidosis: A Case Report
Smith, Jonathan Helmsley, Stovall, Kyndra C., Coons, Stephen W., Fife, Terry D.

Mayo Clinic

Ear, Nose & Throat Journal | January 10, 2019 | Volume: 90 | Issue: 1 | Pages: E1-E3

10.1177/014556131109000111 | PMID 21229491 Get It

We describe the case of a 59-year-old woman who presented with progressive bilateral vestibidar hypofunction and who was found to have bilateral granulomatous mass lesions of the mesial temporal lobe. Initially, her condition stabilized neurologically with corticosteroids, but a diagnosis of neurosarcoidosis was delayed because of the unusual presentation and persistently normal chest imaging results and serum angiotensin-converting enzyme (ACE) levels. Approximately 1 year after her initial presentation, the patient died of complications of a myocardial infarction and pulmonary embolism. Sarcoidosis should be considered in the differential diagnosis of idiopathic bilateral vestibular hypofunction even if the chest imaging and serum ACE levels are normal, particularly when there is evidence of a multisystem process.